SCHEMBL15480533

SCHEMBL15480533

COc1ccc(S(=O)(=O)Nc2ccc(C(=O)NO)cc2)cc1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
LMNA P02545 4/20 0.68
HTT P42858 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
HDAC1 Q13547 4/20 0.67
HDAC4 P56524 3/20 0.67
HDAC8 Q9BY41 4/20 0.65
HDAC6 Q9UBN7 4/20 0.65
HDAC3 O15379 3/20 0.65
HDAC11 Q96DB2 3/20 0.65
HDAC7 Q8WUI4 1/20 0.65
HDAC2 Q92769 1/20 0.65
HDAC10 Q969S8 1/20 0.65
HDAC9 Q9UKV0 1/20 0.65
HDAC5 Q9UQL6 1/20 0.65
ALOX15 P16050 2/20 0.64
MAPK1 P28482 2/20 0.64
CA12 O43570 1/20 0.64
CA9 Q16790 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15482273 0.82 HDAC3 (0.68) MEN1KMT2ALMNAHDAC1HDAC4
SCHEMBL1403545 0.80 HDAC1 (1.00) MEN1KMT2AHDAC1HDAC4HDAC8
SCHEMBL3558972 0.80 WDR5 (0.66) MEN1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL1403549 0.80 HDAC1 (1.00) MEN1KMT2AHDAC1HDAC4HDAC8
SCHEMBL15480531 0.80 SMN1; SMN2 (0.76) MEN1KMT2ALMNASMN1; SMN2HDAC1
SCHEMBL30926682 0.79 ALDH1A1 (0.71) MEN1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL27180955 0.79 ALDH1A1 (0.71) MEN1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL8274490 0.79 HDAC3 (1.00) MEN1KMT2AHDAC1HDAC4HDAC8
SCHEMBL94655 0.79 LMNA (0.77) MEN1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL6508114 0.79 HDAC1 (0.67) MEN1KMT2ALMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 MEN1 4342/4885KMT2A 223/4885LMNA 489/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 MEN1 4342/4885KMT2A 223/4885LMNA 489/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 MEN1 4342/4885KMT2A 223/4885LMNA 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.